the earliest identifier of the choice to develop pluripotency and indeed changing H3R26 methylation status, changes the expression of pluripotency genes and consequently cell fate. Subsequent time-lapse studies of unperturbed embryos revealed that the progeny of the 4-cell blastomere shown to have lowest H3R26 methylation divides symmetrically, thus explaining its biased contribution to trophectoderm [19] . Finally and most recently, 4-cell embryo blastomeres were found to differ in kinetics of the transcription factor Oct4 in a way that further explains their differing fates [20] . Collectively, these studies strongly suggest that at least one cell of the 4-cell embryo differs from the others: this cell's descendants initiate differentiation earlier than those of the other three cells.
Perhaps it is now time to accept that cells in the mouse embryo do not acquire identity in an entirely random (stochastic) manner and that differences between cells can arise as early as the 4-cell stage. It is clear that cells are still developmentally flexible at this point, and even later, but left undisturbed they seem to have 'preferred' paths. An attractive hypothesis that might reconcile many older and newer findings would be that the mouse embryo cells are influenced by where they come from and the circumstances of their parents -they have a memory of their developmental history -but remain flexible enough to adapt to life's new circumstances. This hypothesis illustrates the beauty of this developmental system. Numerous approaches have been devised to show that embryo cells taken from their native environment can flourish when transplanted to new sites; indeed cell properties change upon isolation. What we now need to find out is how these early cells begin to acquire their differences in normal development at a time that precedes the impact of inside versus outside positioning. This will be of great help in understanding the first molecular steps on a path to differentiation on one hand, and on a path to pluripotency on the other. What might the mechanism be? Does it relate to polarisation of the egg or of the zygote? If so, is it influenced by the dramatic asymmetry of the meiotic divisions, asymmetry introduced by sperm entry at fertilisation, or by the behaviour of the male and female pronuclei in the first cell division? Whatever the factor or factors, they are likely to be quite subtle and so their identification presents a challenge, but an exciting one. Second, there is a dramatic asymmetry in the frequency of representation of oncogenic Ras alleles in different tumor types: KRAS has the highest incidence in pancreatic adenocarcinomas (95%) [4] , non-small cell lung cancer (15-20%) [5] , and colon adenomas (40%) [6] ; NRAS mutations appear in hematological malignancies (20-30%) [7] and melanomas (15%) [8] ; and thyroid malignancies harbor mutations in HRAS, KRAS, or NRAS [9] . Consequently, significant effort has been invested in parsing the public versus private occupations of Ras family proteins in order to discover what is special about KRas. One of the most discriminatory features of KRas is a distinctive subcellular localization pattern compared with that of its brothers HRas and NRas. Ras protein tethering to the plasma membrane and/or endomembranes is required for function [10] . The major addressing mechanism for HRas, NRas, and KRas4A is post-translational modification of the carboxyl terminus, with a combination of a farnesyl moiety and palmitoylation [11, 12] . In contrast, the KRAS4B-specific exon encodes a tail that is farnesylated but has a charged polylysine domain instead of the palmitoylation signal [13] . As a consequence, KRas4B bypasses the conventional Golgi secretory pathway to reach the plasma membrane where it is enriched in microdomains that are distinct from those containing HRas and NRas [14] . This spatial segregation is thought to account, at least in part, for a selective capacity of KRas4B to engage downstream effector pathways [14] .
However, these subtleties of regulation may fall by the wayside within some of the most important developmental and pathological contexts. This point was driven home with a series of gene replacement studies in the mouse by Allan Balmain's group. First, the embryonic lethality of homozygous KRAS deletion in mice was rescued by inserting the HRAS coding sequence into the KRAS locus, indicating that HRas protein can fully support embryonic development if expressed with the appropriate timing [15] . Second, these HRAS knock-in mice were fully sensitive to urethane-induced 
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Current Biology Figure 1 . Codon bias may select for the prevalence of KRas mutations in human cancers. Rare codons limit KRas protein translation compared with HRas, which favors accumulation of the latter. Paradoxically, the otherwise subordinate KRas protein may permit mutations at the KRAS locus to escape tumor suppressor surveillance mechanisms. Codon-biased mutant KRas protein is thus free to drive neoplasia en route to tumorigenesis. lung cancer, a phenotype that is normally exclusively associated with activating mutations in KRAS [15] . Remarkably, the lung tumors in the HRAS knock-in animals harbored activating mutations only in HRAS within the KRAS locus, indicating that HRas can fully support tumorigenesis of the lung [15] . Therefore, the frequency of representation of mutations in distinct Ras family members in different tumor types may not be reflective of distinctive biochemical activities as much as it is reflective of differential mutability of the respective genes in different tissues.
In this issue of Current Biology, Chris Counter's group reports another previously unappreciated layer of Ras family regulation that also accounts for distinct Ras family protein activity through distinct contextual features as opposed to biochemical features [16] . Through an investigation springing from sophisticated serendipity, the authors discovered that KRAS is poorly translated compared with HRAS due to stalling of ribosomes on genomically under-represented or rare codons, which are selectively enriched in KRAS transcripts. Converting the rare codons in KRAS to common ones alleviated ribosome stalling and increased the accumulation of KRas protein to concentrations comparable to those observed for HRas. The biological consequence of codon usage was indicated by the observation that HEK-HT cells ectopically expressing a constitutively active form of KRas, KRas(G12V), formed tumors in mice that were w90-fold smaller than those derived from cells ectopically expressing HRas(G12V). This difference was normalized by ectopic expression of the codon-optimized KRas(G12V) variant. When this codon-optimized form of KRas(G12V) was knocked into the KRAS locus of HCT116 cells, their tumor-forming potential increased w30-fold compared with the knock-in control harboring the native complement of rare codons. The finding that KRAS mutation initially delivers a weak oncogene may seem counter-intuitive; however, KRas4B(G12V) can induce apoptosis when phosphorylated at Ser181 and sustained high-amplitude activation of the Raf-MAPK Ras effector pathway can induce cellular senescence through the accumulation of cyclin-dependent kinase inhibitors [17] [18] [19] . Thus, the mechanistic irony is that rare codons may limit KRas expression to concentrations that are below the threshold of anti-neoplastic checkpoint mechanisms but that are sufficient to induce hyperplasia and a regulatory environment permissive to tumor initiation (Figure 1) .
Of great interest will be the elaboration of the regulatory axes that may leverage codon bias to modulate Ras protein function in support of distinct physiological processes. As alluded to above, KRAS is required for embryonic development and the protein is detectable in a variety of embryonic tissues, suggesting the presence of mechanisms that compensate for codon-limited KRas expression. As indicated by the authors, a variety of potential compensation mechanisms have been described, including miRNA regulation, enhanced tRNA production, and -at least in the setting of disease -gene amplification. By extension, the commonality of selective regulation of homologous proteins through codon bias is also an important open question. To begin to address this, Counter and colleagues [16] performed a genome-wide survey for gene pairs encoding proteins with high amino-acid identity but employing opposing codon bias. This analysis returned at least 60 gene pairs, two of which (CFL1/2 and ORMDL1/3) were demonstrated to produce gene products that were selectively limited by the opposing codon bias. Of interest, the cohort of gene pairs was enriched for loci encoding purine nucleotide-binding proteins, including kinases and GTPases, indicating a prevalence of codon bias associated with homologous signaling proteins. This work gives a clear indication that codon bias can play an important role in shaping protein expression profiles. There are 22 mitochondrial tRNA genes and 450 annotated nuclear genes encoding cytoplasmic tRNA molecules [20] . Investigation of the heterogeneity of tRNA expression in animals and its consequence on the assembly of regulatory systems will likely shed additional light on the contribution of codon bias to the time and tissue specificity of protein expression.
